The osteogenic growth peptide (OGPI was characterized recently in regenerating bone marrow (BM) and normal serum. In vitro, the OGP regulates stromal-cell proliferation and differentiated functions. In vivo, an increase in serum OGP accompanies the osteogenic phase of postablation BM regeneration. The present results in normal mice show that OGP induces a balanced increase in WBC counts and overall BM cellularity. In mice receiving myeloablative irradiation and syngeneic or semiallogeneic BM transplants, OGP stimulates hematopoietic reconstruction and doubles the survival rate; these effects are dependent on initiating the OGP administration before irradiation. Chimerism measurements in semiallogeneic graft recipients suggest no preferential effect EGULATION OF hematopoiesis remains an important goal of both clinical and experimental studies. It is particularly relevant for the enhancement of hematopoietic reconstruction to reduce morbidity and mortality in patients subjected to radiotherapy and chemotherapy, as well as after myeloablative chemoradiotherapy and autologous or allogeneic bone marrow transplantation (BMT).'
The osteogenic growth peptide (OGPI was characterized recently in regenerating bone marrow (BM) and normal serum. In vitro, the OGP regulates stromal-cell proliferation and differentiated functions. In vivo, an increase in serum OGP accompanies the osteogenic phase of postablation BM regeneration. The present results in normal mice show that OGP induces a balanced increase in WBC counts and overall BM cellularity. In mice receiving myeloablative irradiation and syngeneic or semiallogeneic BM transplants, OGP stimulates hematopoietic reconstruction and doubles the survival rate; these effects are dependent on initiating the OGP administration before irradiation. Chimerism measurements in semiallogeneic graft recipients suggest no preferential effect EGULATION OF hematopoiesis remains an important goal of both clinical and experimental studies. It is particularly relevant for the enhancement of hematopoietic reconstruction to reduce morbidity and mortality in patients subjected to radiotherapy and chemotherapy, as well as after myeloablative chemoradiotherapy and autologous or allogeneic bone marrow transplantation (BMT). ' Hematopoietic stem cells home to the BM compartment, suggesting a specific affinity of progenitor cell-surface determinants to the BM stroma.* Physiologically, the formation of hematopoietic BM follows new bone formation in the embryo and during repair of bone In addition, bone formation precedes hematopoiesis in instances of heterotopic ossification, such as myositis ossificans and ossicles induced by bone morphogenetic protein^.'.^ Perhaps the most distinct relationship between the formation of bone and BM is that observed after BM injury.',' In this process, an intense osteogenic phase precedes the appearance of a new hematopoietic tissue. In humans and experimental animals, the local osteogenic response is accompanied by a systemic enhancement of bone formation:"' an activity mediated by factors released into the circulation by the healing tissue." Recently, one of these factors, a 14-amino acid peptide, has been characterized and named osteogenic growth peptide (OGP).I3 OGP is identical to the C-terminal sequence of histone H4
and shares a five-residue motif with a T-cell receptor pchain V-region and the Bacillus subtilis outB locus. In vitro, OGP stimulates the proliferation of osteoblastic and fibroblastic cells. When administered to rats, it stimulates bone formation and increases bone mass. OGP in high abundance is present physiologically in human and other mammalian serum, mainly in the form of an OGP-OGP-binding protein c~m p l e x . '~, '~ A marked increase in serum bound and unbound OGP accompanies the osteogenic phase of postablation BM regeneration and associated systemic osteogenic response."
R
Because of both the importance of bone as part of the stromal hematopoietic microenvironment and the OGP stimulation of stromal-cell proliferation and bone formation, the present in vivo experiments were designed to study the peptide's regulatory role in hematopoiesis, in particular after myeloablative irradiation and BMT. 1 0 0 pL PBS, was injected SC every second day to C57 mice. The animals were killed 2 weeks after the onset of treatment. At the time of death, the BM from both femurs was flushed through the distal metaphysis to form a cell suspension in PBS. Differential cell counts were performed in smears stained with polychrome methylene blue/ eosin. Blood samples were obtained from the retroorbital sinus with heparinized glass capillaries immediately before the animals were killed. These samples were subjected to differential WBC counts in a Coulter Counter (Coulter Electronics, Hialeah, FL), as well as RBC and platelet counts.
Effect of OGP on engrafiment of BM transplants. Mice were exposed to a single dose of myeloablative total-body irradiation (TBI) delivered using Clinac 6X Linear Accelerator (Varian Associates, Palo Alto, CA). Twenty-four hours later, the mice were inoculated with a limiting number (4 X IO4 to 1 X IO5) ( Table l) " of BM cells. Syngeneic BMT was performed in CS7 mice receiving 900 cGy TBI. The recipients of semiallogeneic BMT were F, hybrids conditioned with 1200 cGy TB1 and receiving a BM-cell inoculum from either C57 or BALB mice. The treatment consisted of daily injections of 0.001 to IO nmol sOGP in 1 0 0 pL PBS commencing on day 8 before irradiation and until day 4 thereafter. Total BM cell counts were performed 8 days post-BMT in both femora. Some experiments tested the effect of OGP on survival after syngeneic BMT. To assess the OGP differential effect on transplanted donor and residual recipient cells, blood samples from some recipients of semiallogeneic BMT were subjected to chimerism measurements.
Detection of chimerism. Peripheral blood lymphocytes from BALB -. F1 chimeras were separated over a Ficoll-hypaque gradient.
After lysis of residual erythrocytes, the cells were treated with anti-CS7 antiserum and complement or complement alone as described previously'* and the percentage of killed cells determined using trypan blue dye exclusion. Effect of sOGP on . w r m OGP /eve/s. To assess the effect of treatment on the serum OGP levels, normal CS7 mice were administered a single SC dose of 7 X IO-' to 7 X IO' nmol sOGP. The OGP levels were measured in blood samples obtained from the retroorbital sinus 24 to 96 hours later. Because of a possible effect of bleeding on the serum OGP different animals were used in the various time groups.
Serum OGP meas~trements. OGP levels were determined by competitive enzyme-linked immunosorbent assay (ELISA) as reported
The assay was performed using rabbit anti-OGP antiserum generated against N-Ac[(Cys")]OCPconjugated with maleimide-activated keyhole limpet hemocyanin. Steady-state levels were measured in fresh samples. To determine the total OGP. the serum was boiled before the assay. Boiling differentially denatures the OGP-binding protein and releases the intact OGP."
RESULTS
In normal mice, the sOGP induced a greater than 50% increase in the WBC counts and approximately 40% enhancement of the BM cellularity (Fig l) . The proportion of the different cell types was not altered by the OGP treatment (Tables 2 and 3) . suggesting a nondiscriminative enhancement of hematopoiesis. When administered SC in combination with syngeneic BMT, OGP stimulated the femoral cellularity dose dependently between 0.01 and IO nmol/d per mouse. The maximal effect, a twofold stimulation, was triggered by the I -and IO-nmol/d doses (Fig 2) . The initial calibration experiments (data not shown) indicated that this effect was missing unless the OGP treatment began at least 1 week before the ablative radiotherapy and BMT. When dosed optimally with sOGP, 20 of 24 (83%) lethally irradiated mice reconstituted with syngeneic BMT survived at 30 days. In the sham-treated group, only I I of 25 (44%) animals subsisted (Fig 3) . In the OGP-treated group, no deaths occurred after day 14; the preceding mortality rate had been 0.07 mice per day. In the sham-treated group, deaths continued until day 20, with an average 10-fold higher mortality rate (0.7 mice per day) (Fig 3) . The 30-day mortality rate was more than threefold higher in the sham-treated group as compared with OGP-treated mice. When semiallogeneic BMT from C57 or BALB donors was administered to lethally irradiated F, hybrids, recipients treated with sOGP (0.01 nmol daily IV) showed respective twofold and 3.6-fold increases in their total femoral cellularity (Fig 4) . Antibodyinduced killing of peripheral blood lymphocytes from the chimeric mice showed a continuous reduction in the proportion of recipient cells over a 40-day period. This proportion was similar in the sOGP-and sham-treated controls (Table   Table 2 For 4). These measurements of chimerism suggest that the sOGP effect does not discriminate between donor and recipient (possibly residual) hematopoietic cells.
A single SC sOGP dose (0.1 nmol) induced a progressive linear increase in serum immunoreactive OGP (irOGP) concentration that peaked after 48 hours and declined gradually thereafter (Fig 5) . Considering the 2-mL volume of mouse blood, the respective overall enhancement of the steady state and total irOGP content was approximately fourfold and 34-fold higher than the amount of injected sOGP. An experiment designed to further explore the Occurrence of a possible feedback regulation of the serum OGP content, showed that SOGP, administered once, stimulates the endogenous peptide levels dose dependently (Fig 6) . The total and steady-state irOGP levels were increased by 7 X to 7 X 10" and 7 X to 7 X 10" nmol, respectively, followed by a dose-response reversal of the stimulatory effect at higher doses (Fig 6) .
DISCUSSION
The present results demonstrate that OGP treatment enhances the blood cellularity of normal mice under resting conditions, as well as the engraftment of BMT in myelo- ablated recipients. The differential cell counts in both the blood and BM show that OGP induces a multilineage nondiscriminative stimulation of WBCs, RBCs, and platelets. This is an important feature that distinguishes OGP from many of the hematopoietic polypeptide factors, such as the colonystimulating factors, some of the interleukins, and erythropoietin, which, unless administered in synergistic combinations, affect preferentially well-defined hematopoietic Another recently reported hemoregulatory synthetic peptide, SK&F107647, also has a multilineage This effect is probably mediated by enhancement of cytokine production by stromal ~e l l s . '~-~~ However, it is rather unlikely that the SK&F107647 increases the production of all the cytokines to the same extent and therefore differences in the magnitude of mitogenic stimulation of the different hematopoietic lineages are to be expected. In fact, an effect of SK&F107647 on the number of terminally differentiated hematopoietic cells has not yet been shown. On the other hand, the OGP increases similarly the number of all morphologically differentiated hematopoietic cells, suggesting a mitogenic effect on early progenitors or cells expressing hematopoietic regulatory polypeptides.
In addition to its stimulatory effect on hematopoiesis in normal mice, OGP enhances hematopoietic reconstitution after syngeneic and semiallogeneic BMT in lethally irradi- For week post-BMT. That the newly established hematopoietic tissue is indeed functional is shown by our survival experiments in which the 30-day mortality rate was threefold higher in sham-treated control than OGP-treated recipients. The mechanism of the OGP stimulation of the BMT engraftment appears to differ from that of the hematopoietic growth factors. These factors are targeted directly to hematopoietic progenitors"'.'' and therefore applied to minimize the pancytopenic risk period by ( I ) expansion and mobilization in vivo, or ex vivo, of autologous and allogeneic cell inoculi before cryopreservation and transplantation, respectively,3"" or (2) administration to recipients commencing at the time of transplantation or shortly thereafter.3s.'"' On the other hand, in the case of the OGP acceleration of BM regeneration post-BMT, it seems essential to initiate treatment at least 1 week before ablative radiotherapy and BMT. The progressive decline in host-derived WBC counts (percent killed C57-marker-bearing cells), which was similar in OGP and PBS-treated chimeric recipients, suggests that unlike interleukin-l, for example," preirradiation OGP treatment does not confer radioprotection to hematopoietic progenitors. The present data therefore implicate OGP in the acceleration of hematopoiesis secondary to an expansion of the stromal microenvironment" and/or enhancement of stroma-derived signaling to hematopoietic stem cells.'x This conclusion is supported by the following considerations: The stromal cells are substantially more radioresistant than their hematopoietic counterparts'""') and their proliferation is accelerated by It is not unlikely that this is also the in vivo scenario inasmuch as OGP administration to experimental animals induces an increase in osteoblast number, bone formation, and trabecular bone mass." Osteoblasts and other stromal cells express an array of hematopoietic regulatory polypeptides'5-'".'' and, therefore, a closely matched multilineage acceleration of hematopoiesis would be anticipated if the OGP mitogenic upregulation of these cells is well balanced.
To explain the low-dose effectiveness of the OGP treatment we performed postadministration measurements of serum irOGP. Most of the serum OGP is complexed to a binding proteinr3"': the bound and most of the unbound irOGP is identical to OGP( l-I4).l4 The unbound OGP levels are represented by the steady-state irOGP, which is a substantial overestimation useful only for comparative purposes."." It is the unbound OGP that presumably conveys the peptide's biologic activity. through a tightly controlled release of unbound OGP from the complex. This relationship between sOGP administration and endogenous peptide levels is consistent with an autocrine positivehegative feedback loop at low and high doses, respectively. Similar feedback loops have been reported for other polypeptide factors present in the serum, such as interleukin-2, interleukin-12, platelet-derived growth factor, and transforming growth factor Clinical trials using currently available preparations for stimulating hematopoiesis consist mainly of the administration of recombinant cytokines such as granulocyte colonystimulating factor, granulocyte-macrophage colony-stimulating factor, and various i n t e r l e~k i n s .~~-~~ Most of these cytokines enhance preferentially proliferation of progenitor cells already committed to particular WBC lineages. Consequently, the critical time to neutrophil recovery is decreased.49 However, these agents do not elicit an overall balanced multilineage response and, hence, protracted anemia and thrombocytopenia frequently remain major clinical problems. Furthermore, there are some major concerns regarding the therapeutic use of hematopoietically active cytokines, because some tumors, and especially leukemic cells, possess normal receptors for these c y t o k i n e~~~~~' and their administration can increase relapse rates by enhancing the proliferation of residual recipient tumor cells that may escape chemoradiotherapy. In contrast, OGP may offer a balanced reconstruction of hematopoiesis after high-dose radiotherapy and chemotherapy and after BMT. If indeed OGP acceleration of hematopoiesis is secondary to the peptide's effect on the stromal microenvironment and unaccompanied by direct stimulation of recipient cells, then OGP treatment would be especially useful in cases of hematopoietic malignancies. Indeed, preliminary results in our laboratory show that OGP does not affect the number of transplanted malignant hematopoietic cells (data not shown). OGP-based therapy is particularly attractive because of the physiologic natural occurrence of the peptide in man.I4 Furthermore, OGP can be readily synthesized and replace or supplement expensive recombinant hematopoietic cytokines.
